ACI's Acclaimed Summit on Life Sciences IP Due Diligence is taking place virtually November 9-10, 2020
Meet thought leaders from top Life Sciences companies that will help you develop strategies for the best results of the IP due diligence process.
NEW YORK CITY, UNITED STATES, October 26, 2020 /EINPresswire.com/ -- ACI is excited to offer our 4th Annual Summit on Life Sciences in an interactive, virtual format. This is the only forum devoted to providing corporate and IP counsel with expert strategies for assessing, valuing and commercializing IP assets when conducting strategic due diligence on any deal.
Gain insights from Key Industry Stakeholders including:
• Akebia Therapeutics
• Akorn Pharmaceuticals
• Boehringer Ingelheim USA Corporation
• Cantel Medical
• Eisai Inc.
• Eli Lilly and Company
• Flagship Pioneering
• Genentech
• Gilead Sciences
• Merck
• Novartis Pharmaceuticals
• Omega Therapeutics
• Pieris Pharmaceuticals
• Roche
• Sanofi
• Takeda
New, interactive sessions will have you fully engaged and learning from senior industry insiders. Sessions include:
• Interactive Ethics Lab: Overcoming Common Challenges and Ethical Dilemmas in Life Sciences IP Due Diligence
• Interactive Case Study: Avoiding Missteps When Conducting IP Due Diligence in Connection with Distressed Companies and Distressed Assets
• Pre-Conference Primer: Life Sciences IP Due Diligence 101 – Preparing Your Due Diligence Checklist and Managing the Process from Soup to Nuts
• Freedom to Operate BootCamp: A Comprehensive Tactical Guide to Mastering the FTO Search
To see our full list of speakers, view the brochure.
Shannon Kao
American Conference Institute
s.kao@canadianinstitute.com
Visit us on social media:
Twitter
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
